In this paper, we evaluated whether adipocytes differentiated from adipose-derived stem cells (ASCs) of normal, overweight, or obese individuals could promote resistance to bortezomib or a triple-drug combination of bortezomib, lenalidomide, and dexamethasone in MM cells, and the extent to which this was mediated through P-glycoprotein (MDR1) and/or CAM-DR pathways. Here, ABCB1 is linked to Miyoshi myopathy.